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The z ratio was calculated as a sum of LV ejection and filling times divided by RR inter- 
val. 
Results: During pacing, average regional strain improved from -6.6 ± 9.4 to -8.8 ± 8.2 % 
(p = 0.02) (Figure), with no change in average regional displacement (0.41 ± 0.09 vs. 
0.42 ± 0.29, p = NS). Peak power index improved from 82 ± 28 to 94 ± 28 mmHgx m/s (p 
= 0.04) while systolic blood pressure increased from 106 ± 36 to 111 ± 32 mmHg (p = 
0.05). Finally, the z ratio increased from 0.76 ± 0.09 to 0.85 ± 0.04 (p = 0.002). 
Conclusion: Using novel, but widely available, noninvasive indices we demonstrated 
improvement in regional and global LV systolic function during biventricular pacing. 
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1111-161 Effect  o f  Beta-Blockade Therapy in Symptomatic Heart 
Fai lure Pat ients  With and Wi thout  Left  Bundle Branch 
Block 
Andreas Schuchert. for the BISEX Investigators, University-Hospital Hamburg- 
Eppendoff, Hamburg, Germany. 
Patients with advanced heart failure and left bundle branch block benefit from the implan- 
tation of a coronary sinus lead for electrical resynchronization. Most previous studies, 
however, included patients who had not yet received beta-blocker treatment. The aim of 
the present investigation was to compare the effect of beta-blocker treatment in patients 
with and without left bundle branch block on NYHA-class. The study included 382 out- 
clinic patients with advanced heart failure who already received an ACE inhibitor and 
diuretics. The patients received in 2-weeks interval increasing doses of bisoproIoI from 
1.25 mg to 10 mg daily, Mean follow-up was 27 weeks after initiation of beta-blocker 
treatment. 
Results: There were 107 (64 ± 9 years, male n = 70) patients with (LBBB) and 275 (62 ± 
10 years, male n = 201) patients without left bundle branch block (CON). The study was 
prematurely terminated in 18 (17%, LBBB) and 48 (17%, CON) patients, respectively. 
The reasons were adverse events (n--46), lost-to-follow-up (n=8), withdrawn consent 
(n=5) and various others (n=7). The mean follow-up time was 28 ± 10 weeks in the LBBB 
and 26 ± 11 weeks in the CON group. The maximal beta-blocker dose was 7.2 ± 3.2 mg 
(LBBB) and 7.1 ± 3.1 mg (CON) daily, respectively. Heart rate decreased from 81 ± 15 
(LBBS) and 80 ± 13 bpm (CON) by 14 bpm in each group. NYHA class I had 4 (4%) with 
and 16 (6%) without LBBB, NYHA class II 55 (51%) with and 158 (58%) without LBBB, 
NYHA class III 47 (44%) with and 101 (37%) without LBBB, and NYHA class IV 1 (1%) 
with and 0 without LBBB. At the final evaluation, NYHA class I had 31 (29%) with and 91 
(33%) without LBBB, NYHA class II 63 (59%) with and 167 (61%) without LBBB, NYHA 
class III 10 (9%) with and 16 (6%) without LBBB, and NYHA class IV 3 (3%) with and 1 
(0.4%) without LBBB. There were no significant differences in the improvement of the 
two groups. 
Conclusions: Patients with advanced heart failure and left bundle branch block had the 
same benefits from beta-blocker treatment compared to patients without left bundle 
branch block. Beta-blocker treatment should be initiated in these patients before an inva- 
sive resynchronization therapy is considered. 
1111-162 The Prevalence of Heart Fai lure in the Permanently 
Paced Population and the Uti l i ty of  BNP as a Screening 
Tool  
Simon D. Thackrav. Klaus K. Witte, Nikolay P. Nikitin, John G. Cleland, Academic 
Department of Cardiology, University of Hull, Kingston-upon-Ruff, United Kingdom. 
Background: We undertook a detailed clinical and echocardiographic screening study of 
patients with permanent ventricular pacemakers (PPM) to describe the prevalence of 
heart failure and the use of BNP as a screening tool. 
Method: 300 consecutive patients attending for routine follow up at a regional cardio-tho- 
racic centre were enrolled. Mode and duration of pacing were recorded along with symp- 
toms, medical history, 6-minute walk, n-terminal BNP, and a detailed echocardiogram. 
Results: 150 patients had a DDD device (mean age 69.3 SD 11.3 years) and 133 a VVI 
device (mean age 75,4 SD 12.2 years P=0.0015 for age). 69 patients (23%) had heart 
failure (HF), as defined by symptoms of breathlessness (NYHA class II, IIJ or IV) and a 
Simpson's hi-plane ejection fraction (LVEF) of 40% or less. Patients with HF had had a 
PPM for significantly longer (8.4 SD 6.8 vs, 3.9 SD 3.4 years P=0,0046), were more likely 
to have a VVI than a DDD PPM (26 of 150 DDD vs. 43 of 133 VVI chi squared=6.3, 
P=0.01) and a significantly reduced 6 minute walk distance 107 (66) m vs. 249 (146) m, 
P=O.0001. 
BNP data were analysed on 250 patients (125 DDD, 115 VVl and 10 others). Mean BNP 
values were higher in the VVl group (406 fmol/ml SD 504) vs. DDD (274 fmol/ml SD 233) 
P=0.001. BNP level was inversely correlated with LVEF in all patients (r = -0,409, 
p=0.001). This relationship was stronger in the DDD group (r = -0.62, P<0.001) than the 
VVI group(r = -0.24, P=0.06). Overall sensitivity (sn) and specificity (sp) of plasma SNP 
level for detecting HF was moderate in the paced population. Sub-group analysis by 
pacemaker type showed much-improved sp/sn in the DDD group. Values above 350 
fmol/ml (upper limit of normal) offered 69.2% Sn and 89.1% Sp (+ve predictive value 
0.64, -ve predictive value 0.91) in the DDD group, this increased to 72.7% / 92.8% (+ve 
PV 0.8, -ve PV 0.89) if as,symptomatic patients were excluded. 
Conclusion: Heart failure is present in neady a quarter of the paced population. Echocar- 
diographic screening of this 'at-dsk' population is justified to improve rates of diagnosis 
and treatment. N-terminal BNP may be a valuable adjunct in screening patients with a 
DDD pacemaker, offering good exclusion value for heart failure. 
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1112-151 The Sever i ty  of  Bra in  In jury  and Female Gender Predict 
Myocardial Necrosis After Subarachnoid Hemorrhage 
Povee P. Tuna, Alexander Kopelnik, Nader M. Banki, Kenneth C. Ong, Nerissa U. Ko, 
Michael T, Lawton, Daryl R. Gress, Barbara Drew, Elyse Foster, William W. Parmley, 
Jonathan G. Zaroff, UCSF Medical Center, San Francisco, Ca/ifomia. 
Background:. Cardiac injury is common after subarachnoid hemorrhage (SAH) and 17% 
of patients have elevated levels of cardiac troponin I (cTi). However, the clinical predic- 
tors of myocardial necrosis are unknown. The objective of this study was to determine 
the demographic, hemodynamic and neurologic factors that predict release of cTi. 
Methods:. We conducted a prospective cohort study of consecutive patients admitted to 
UCSF with SAH. Predictor variables reflecting demographic (age, gender), hemody- 
namic (phenylephdne dose, head rate, systolic blood pressure) and neurologic factors 
(Hunt-Hess clinical SAH severity score, 1-5) were acquired, The hemodynamic data was 
collected and cTi was measured on days 1, 3, and 6 after enrollment. Troponin I was 
treated as a dichotomous outcome variable (abnormal >0,3 ug/L). We performed bivad- 
ate and multivariate statistical analyses to determine the odds ratio (OR) for cTi release 
for each predictor variable. 
Results: The study subjects included 99 patients, 64 women and 35 men, with an aver- 
age age of 53. Elevated cTi levels occurred in 36.5% (range 0.4-50 ug/L), cTi was ele- 
vated in all four patients with Hunt-Hess grade 5 SAH (not modeled). The statistical 
results are shown below: 
Predictor Bivadate Analysis Multivariate Analysis 
OR 95% CI P OR 95% CI P 
Hunt-Hess 2 (vs.1) 0.64 0.11-3.49 0.604 0.44 0.07-2.78 0.389 
Hunt-Hess 3 (vs.1) 3.82 1.22-11.94 0.021 3.49 0.95-12.77 0.059 
Hunt-Hess 4 (vs.1) 9.11 2.38-34.85 0.001 10.29 2.14-49.53 0.004 
Female Gender 2.68 1.05-6.83 0,039 5.50 1.49-20.34 0.011 
Age (per 5/yr incr.) 1.01 0.86-1.19 0.878 0.84 0.64-1.09 0.183 
Peak Phenylephdne Dose 1.05 1.01-1.10 0.029 1.04 0.98-1.10 0.232 
(per 20mcg incr.) 
Peak Heart Rate 1.01 0.99-1.03 0.393 0.99 0.96-1.02 0.415 
Peak Systolic BP 1.01 0.99-1.02 0.396 1.01 0.99-1.04 0.334 
Conclusion: The severity of neurologic injury and female gender are strong independent 
predictors of myocardial necrosis in patients with SAH. Patients with these characteris- 
tics should be closely monitored for the development of cardiac dysfunction. 
1112-152 Card ioneuropathy  and Mi tochondr ia l  Phenotype 
Jose Marin-Gamia. Michael J. Goldenthal, The Molecular Cardiology and Neuromuscular 
Institute, Highland Park, New Jersey 
Cardiomyopathy and neuromuscular abnormalities (cardioneuropathy) may simulta- 
neously coexist and present with defects in mitochondrial DNA and bioenergetic function. 
Methods: A combined biochemical and molecular analysis of mitochondda was per- 
formed in 14 patients with both cardiomyopathy (8 with HCM, 6 with DCM) and neurolog- 
ical disorders including ataxia, seizures, dystonia, ophthalmoplegia, Kearns-Sayre 
syndrome (KSS) and Leigh disease. 
Results: All cardiac tissues analyzed (8 cases) showed defects in specific cardiac mito- 
chondrial respiratory complex activity (5 with multiple enzymes effected; 3 with a single 
enzyme effected). Both Leigh cases had defects in complex V associated with a mtDNA 
mutation at nt 8993; other pathogenic mtDNA mutations reported in mitochonddal dis- 
ease were not found. The most frequent cardiac enzyme effected was complex V (7 of 8 
cases). All skeletal muscle tissues analyzed (6 cases) had at least 2 respiratory enzymes 
effected with complex III most frequently effected (all 6). No pathogenic mtDNA point 
mutations were found in this group. However, two patients (with DCM and KSS) dis- 
played highly abundant, multiple large-scale skeletal muscle mtDNA deletions (including 
a novet 11 kb deletion) as well as reduced complex I,III and IV ectivities.Analysis of blood 
from one patient presenting with ataxia and DCM revealed multiple, abundant large-scale 
mtDNA deletions. 
Conclusion: Defects in mitochondrial DNA and bioenergetics are frequently present in 
cases of cardioneuropathy and may be causally related mainly in the presence of specific 
mtDNA point mutations (2) and deletions (4). Biochemical and molecular analysis of 
mitochondria is warranted in the evaluation of cardioneuropathy. 
